Robert H. Pierce is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of immunology, particularly in cancer research. With a total of 3 patents, his work focuses on advancing diagnostic and therapeutic techniques.

Latest Patents

One of his latest patents is an "Immunohistochemical assay for detecting expression of programmed death ligand 1 (PD-L1) in tumor tissue." This patent provides processes for describing and quantifying the expression of human programmed death ligand-1 (PD-L1) in tumor tissue sections. The assay utilizes an antibody that specifically binds to PD-L1, and the results generated have various experimental, diagnostic, and prognostic applications.

Another significant patent is the "Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue." This patent describes an IHC assay for detecting and quantifying spatially proximal pairs of PD-1-expressing cells and PD-Ligand-expressing cells in tumor tissue. The assay aims to generate proximity biomarkers that predict which cancer patients are most likely to benefit from treatment with a PD-1 antagonist.

Career Highlights

Robert H. Pierce is currently associated with Merck Sharp & Dohme Corporation, where he continues to innovate in the field of immunology. His work has the potential to significantly impact cancer treatment and patient outcomes.

Collaborations

He has collaborated with notable coworkers, including Patricia Bourne and Linda Liang, contributing to a dynamic research environment that fosters innovation.

Conclusion

Robert H. Pierce's contributions to immunology and cancer research through his patents demonstrate his commitment to advancing medical science. His innovative work continues to pave the way for improved diagnostic and therapeutic strategies in oncology.

This text is generated by artificial intelligence and may not be accurate.